Active idiotypic vaccination versus control immunotherapy for follicular lymphoma
Granulocyte-Macrophage Colony-Stimulating Factor
This trial failed to demonstrate clinical benefit of specific immunotherapy. The subset of vaccinated patients mounting specific anti-Id responses had superior outcomes. Whether this reflects a therapeutic benefit or is a marker for more favorable underlying prognosis requires further study.